Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Investors Who Have Incurred Losses With Humana Inc Are Motivated By The Schall Law Firm To Reach Out

LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Investors Who Have Sustained Losses With Humana Inc Are Encouraged By The Schall Law Firm To Connect

SAN DIEGO , July 2, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Humana Inc. (NYSE: HUM) shares. Investors, who purchased Humana Inc. (NYSE: HUM) shares prior to July 27, 2022 and continue to hold any of those NYSE: HUM shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

NYSE: HUM Lawsuit Alert: Investors who lost money with shares of Humana Inc. should contact the Shareholders Foundation

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the “Class Period”), of the important August 2, 2024 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages Humana Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HUM

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=88637&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 2, 2024 in Humana Lawsuit – HUM

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humana Inc. (NYSE: HUM).

Shareholders that lost money on Humana Inc.(HUM) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Calls On Investors Who Have Sustained Losses With Humana Inc To Contact

CVS Health

UnitedHealth Group

The probability of Donald Trump returning to the White House currently sits at about 60%, as per Andrew Lilley – the chief interest rate strategist at Barrenjoey. And if Joe Biden's Republican rival does indeed win the 2024 U.S. elections, the following three health insurance stocks will likely benefit.

These three healthcare stocks will benefit if Trump wins in 2024

LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Investors Who Have Suffered Losses With Humana Inc Are Invited By The Schall Law Firm To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Appeals To Investors Who Have Experienced Losses With Humana Inc To Connect

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., June 28, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the “Class Period”), of the important August 2, 2024 lead plaintiff deadline.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humana Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HUM

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Investors Who Have Endured Losses With Humana Inc Are Prompted By The Schall Law Firm To Get In Touch

NEW YORK , June 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humana Inc. (NYSE: HUM). Shareholders who purchased shares of HUM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Humana Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUM

NEW YORK , June 27, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the "Class Period"), of the important August 2, 2024 lead plaintiff deadline. So what: If you purchased Humana common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Humana Inc. Sued for Securities Law Violations - Investors Should Contact The Rosen Law Firm Before August 2, 2024 to Discuss Your Rights - HUM

Humana's (HUM) subsidiaries team up with PsychArmor to enhance veteran care, offering specialized training at 23 senior primary care centers in Texas, thereby attracting more members of the targeted community to the centers.

Humana (HUM) Ties Up With PsychArmor for Better Veteran Care

NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humana securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period").

HUM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Humana Inc. Investors to Join the Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / June 27, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=87846&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on Humana Inc.(HUM) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Encourages Investors Who Have Incurred Losses With Humana Inc To Make Contact

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the second quarter 2024 (2Q24), as well as prepared management remarks (in PDF format), on Wednesday, July 31, 2024, at 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024. To participate via telephone, please register in advance using this link, https:/.

Humana Inc. to Release Second Quarter 2024 Results on July 31, 2024

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=87725&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Humana Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 2, 2024 – HUM

Humana Inc HUM recently inked an in-network deal with the University of Alabama at Birmingham's (UAB) Health System to provide Medicare Advantage members in the state greater access to care.

Humana Has A 'Positive 6-Month Catalyst Path,' Says Bullish Analyst

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Urges Investors Who Have Suffered Losses With Humana Inc To Contact

LOUISVILLE, Ky.--(BUSINESS WIRE)--Conviva and CenterWell are partnering with PsychArmor to ensure healthcare providers are 'Veteran Ready' with military cultural competency training.

Conviva and CenterWell partner with PsychArmor to ensure healthcare providers are Veteran Ready

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Urges Investors Who Have Suffered Losses With Humana Inc To Connect

A lawsuit was filed for certain investors in Humana Inc. (NYSE: HUM) shares. Investors in NYSE: HUM shares should contact the Shareholders Foundation.

News for Humana Stock (HUM)